Soluble polypeptides for use in treating autoimmune and inflammatory disorders
AssigneeNovartis AG
InventorsMarianne Raymond, Marie Sarfati, Karl Welzenbach, Maximilian Woisetschlaeger
Life of this patent
Estimating the term…
Abstract
The present invention relates to soluble CD47 binding polypeptides, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble CD47 binding polypeptide for use as a medicament, comprising an extracellular domain of SIRPα (CD172a) or functional derivatives which bind to human CD47.
Claims20
A soluble CD47 binding polypeptide for use as a medicament, comprising a SIRPα-derived polypeptide selected among the group consisting of:
- a) an extracellular domain of SIRPα (SEQ ID NO:3);
- b) a fragment of SEQ ID NO:3, and,
- c) a variant polypeptide of SEQ ID NO:3 having at least 75% identity to SEQ ID NO:2;
- wherein said SIRPα-derived polypeptide binds to human CD47 (SEQ ID NO:24).
(canceled)
(canceled)
Dependencies are inferred from the claim text.